Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Omid Hamid

Showing results (11-20 of 188) with videos related to

Pageof 19
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Selecting patients for KIT inhibition in melanomaRichard D Carvajal, Omid Hamid, Cristina R Antonescu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2022
Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the FutureAllison Betof Warner, Pippa G Corrie, Omid Hamid
Journal of Surgical Oncology|August 23, 2011
Systemic treatment of metastatic melanoma: new approachesOmid Hamid, Peter D Boasberg, Katherine Rosenthal, et al.
Current Medical Research and Opinion|August 31, 2019
Treatment patterns of malignant melanoma in the United States from 2011 to 2016: a retrospective cohort studyShweta Shah, Leon Raskin, David Cohan, et al.
Cancer Immunology, Immunotherapy : CII|July 17, 2017
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancerOmid Hamid, Brianna Hoffner, Eduard Gasal, et al.
Melanoma Management|December 25, 2019
Treatment patterns of melanoma by <i>BRAF</i> mutation status in the USA from 2011 to 2017: a retrospective cohort studyShweta Shah, Leon Raskin, David Cohan, et al.
Human Vaccines & Immunotherapeutics|May 21, 2026
Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product reviewJonathan E Cohen, Inderjit Mehmi, Mordechai Avner, et al.
Cancers|October 27, 2019
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant MelanomaOmid Hamid, C Lance Cowey, Michelle Offner, et al.
Nature Reviews. Clinical Oncology|April 26, 2022
Optimal systemic therapy for high-risk resectable melanomaAlexander M M Eggermont, Omid Hamid, Georgia V Long, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2022
Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective StudyArtak Labadzhyan, Kristopher Wentzel, Omid Hamid, et al.
Pageof 19

Showing results (11-20 of 188) with videos related to

Sort By:
Pageof 19
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Selecting patients for KIT inhibition in melanomaRichard D Carvajal, Omid Hamid, Cristina R Antonescu
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2022
Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the FutureAllison Betof Warner, Pippa G Corrie, Omid Hamid
Journal of Surgical Oncology|August 23, 2011
Systemic treatment of metastatic melanoma: new approachesOmid Hamid, Peter D Boasberg, Katherine Rosenthal, et al.
Current Medical Research and Opinion|August 31, 2019
Treatment patterns of malignant melanoma in the United States from 2011 to 2016: a retrospective cohort studyShweta Shah, Leon Raskin, David Cohan, et al.
Cancer Immunology, Immunotherapy : CII|July 17, 2017
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancerOmid Hamid, Brianna Hoffner, Eduard Gasal, et al.
Melanoma Management|December 25, 2019
Treatment patterns of melanoma by <i>BRAF</i> mutation status in the USA from 2011 to 2017: a retrospective cohort studyShweta Shah, Leon Raskin, David Cohan, et al.
Human Vaccines & Immunotherapeutics|May 21, 2026
Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product reviewJonathan E Cohen, Inderjit Mehmi, Mordechai Avner, et al.
Cancers|October 27, 2019
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant MelanomaOmid Hamid, C Lance Cowey, Michelle Offner, et al.
Nature Reviews. Clinical Oncology|April 26, 2022
Optimal systemic therapy for high-risk resectable melanomaAlexander M M Eggermont, Omid Hamid, Georgia V Long, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2022
Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective StudyArtak Labadzhyan, Kristopher Wentzel, Omid Hamid, et al.
Pageof 19